Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ani Pharmaceuticals (ANIP) Non Operating Income (2016 - 2025)

Ani Pharmaceuticals (ANIP) has disclosed Non Operating Income for 14 consecutive years, with $850000.0 as the latest value for Q4 2025.

  • Quarterly Non Operating Income rose 161.68% to $850000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.9 million through Dec 2025, up 147.95% year-over-year, with the annual reading at $1.9 million for FY2025, 147.95% up from the prior year.
  • Non Operating Income hit $850000.0 in Q4 2025 for Ani Pharmaceuticals, up from -$853000.0 in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $1.7 million in Q2 2025 to a low of -$2.7 million in Q4 2021.
  • Historically, Non Operating Income has averaged -$296550.0 across 5 years, with a median of -$47500.0 in 2022.
  • Biggest five-year swings in Non Operating Income: tumbled 6400.0% in 2024 and later skyrocketed 2076.14% in 2025.
  • Year by year, Non Operating Income stood at -$2.7 million in 2021, then skyrocketed by 98.44% to -$42000.0 in 2022, then rose by 21.43% to -$33000.0 in 2023, then tumbled by 4075.76% to -$1.4 million in 2024, then surged by 161.68% to $850000.0 in 2025.
  • Business Quant data shows Non Operating Income for ANIP at $850000.0 in Q4 2025, -$853000.0 in Q3 2025, and $1.7 million in Q2 2025.